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Chronic lymphocytic leukaemia with
transformation into a large cell lymphoma
(Richter's syndrome) is usually associated with
the rapid demise of these already
immunocompromised patients. There have been
no previously recorded cases involving the nose.
We report such a case and describe a successful
treatment approach combining monoclonal
antibody therapy with ao mini-allogeneic bone
marrow transplant.
CASE REPORT A 54-year-old man presented
totheotolaryngologydepartmentwith aswelling
onthedorsumofthenose,whichhadbeenrapidly
enlarging for one month. Two years prior to this
he was diagnosed with chronic lymphocytic
leukaemia(CLL) andwas stabilisedinitially with
six courses of Chlorambucil. He relapsed one
yearlaterandbone marrow assessmentfollowing
furthertreatment with six courses ofFludarabine
showed only a partial response. One year further
onhepresentedwiththenose swelling. Hehadno
symptoms suggestive of systemic involvement.
On examination there was a 2 x 2.5cm soft mass
on the dorsum ofthe nose continuous with ablue
swellingobstructingtheleftnostril.Theremainder
of his physical examination was unremarkable.
An axial CT scan (fig. 1) ofhis paranasal sinuses
demonstrated a soft tissue mass, closely related
to the left side of the anterior nasal septum, 2cm
in diameter. Bowing ofthe nasal septum, as seen
in the coronal reconstructions (fig 2) suggested
the mass had been present for some time while
theco-existing opacification ofthe leftfrontal air
cell is a feature of sinus outflow obstruction.
Anintranasal incisionalbiopsyconfirmedahigh-
grade large cell transformation of the CLL -
Ricfiter's Syndrome.' He was treated with a six
cycle chemotherapy regime of
Cyclophosphamide, Hydroxorubicin, Vincristine
and Prednisolone (CHOP) commencing two
months after the swelling presented. It resolved
andfollow-upMRIscanatsixmonthswasnormal.
Thepatientwassubsequentlytreatedwithafurther
course of Fludarabine and the monoclonal
antibody, CAMPATH-1H, before receiving a
mini-allogeneic bone marrow transplantfromhis
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brotheroneyearfrompresentation. APCR-based
assay showed that complete haemotopoietic
chimaerism was achieved after the transplant,
however, he also had low-grade graft versus host
disease.
Presently, three and half years from initial
presentation, he has a normal quality of life in
continuing complete remission from both the
transformed disease and the CLL.
DISCUSSION
Richter's syndrome refers to the development of
aggressive non-Hodgkins Lymphoma during the
course of chronic lymphocytic leukaemia.
Affecting 5% ofthese patients, it represents one
ofthe possible anaplastic transformations of the
leukaemia.2 Diseaseonsetistypicallymanifested
by a sudden clinical deterioration of the patient
and is characterised by rapid progression of
lymphadenopathy, by extranodal disease and by
constitutional symptoms. Histological
examination is required to make thediagnosis of
high-grade lymphoma. Immunophenotyping of
the cells taken from the tissue biopsy and from a
bone marrow aspirate expressed the same cell
surface Kappa light chains suggesting clonal
evolution rather than new disease.3
Robertson et al report a modest 5-month median
survival despite multiagent therapy.4 There is
some evidence that patients may do quite well
after high dose chemotherapy with stem cell
support. Rodriguez et al have published data
suggesting an improved prognosis in a series of
patients receiving high dose chemotherapy
followed by allogeneic bone marrow
transplantation.5
Despite resolution of the nasal lesion following
the CHOP regime the patient also underwent a
bone marrow transplant and treatment with
monoclonal antibody in order to provide him
with the best chance of achieving complete
remission. A high-dose conditioning regime is
normally used prior to bone marrow
transplantation. However,previoustreatmentwith
chemotherapy precluded mobilisation of
autologous peripheral blood stem cells neededto
compensate for the bone marrow suppression,
which normally occurs following such a regime.
He was therefore treated with a reduced dose of
Fludarabine and CAMPATH-1H, a monoclonal
antibody against CD52, an antigen expressed on
greater than 95% of all normal human blood
lymphocytes and most B and T cell lymphomas.6;7
In the first report of the antibody, tumour
regressionwas seenintwopatientswithadvanced
non-Hodgkin's lymphoma treated with
CAMPATH-1H.8 It is currently recommended
for the treatment of patients with Fludarabine
refractory CLL andpreliminary data suggest itis
effectiveasafirstlineagentinthetreatmentofB-
cell CLL.9; 10 By activating various immune
effectorfunctions,includingantibody-dependent
cellularcytotoxicity, theantibodynotonlytargets
tumour cells, it temporarily destroys the
recipient's T-cells. Theresultantcomplete donor
chimaerism may reduce the risk of transplant
rejection and confer a survival advantage.1" The
"mini" from mini-allogeneic transplant refers to
the reduced dose of chemotherapy used.
To the best ofour knowledge there have been no
previously reported cases affecting the nose to
date. Ahandfulofcaseshavebeendescribedwith
skin involvement, however, it is rarely limited to
cutaneous locations.12
It is our aim to highlight not only this novel
presentation but also the encouraging result
obtained from new treatment techniques with
monoclonal antibody and the reduced intensity
conditioning chemotherapy regime.
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